DeepMind points its AI tools at antibiotic-resistant infections
Google DeepMind is using AI to help scientists find new drug targets against superbugs, a problem tied to millions of deaths. No results are reported yet.
The short version
- Antimicrobial resistance (AMR) means bacteria, viruses and fungi evolve to evade existing treatments.
- Public health studies project up to 10 million deaths by 2050 without new drugs.
- DeepMind uses Google Antigravity, an agent-based platform, to help scientists assess protein structures and design compounds.
- Its ProtNLM model flags poorly described proteins in the UniProt database as possible new targets.
- MIT is also using generative AI against drug-resistant gonorrhea and MRSA.
Why it matters
Drug-resistant infections make routine care riskier, and few new antibiotics are arriving. If AI can speed up the early search for drug targets, it may help close that gap. For now this is a direction of travel, not a proven result.
A slow-moving health emergency
Antimicrobial resistance, or AMR, happens when germs change so that the drugs once used to kill them stop working. Infections then take longer to treat, and patients face a higher risk of dying.
As technews.tw reported, public health studies estimate AMR could cause up to 10 million deaths by 2050 if no effective new drugs or therapies appear. The US CDC says nearly 5 million people worldwide died of resistance-related infections in 2019 alone.
What DeepMind is actually using
DeepMind is focusing on structural biology, the study of the 3D shapes of proteins, and on generative models, which create new outputs such as candidate molecules. It is using Google Antigravity, an agent-based development platform, to help scientists judge protein structures, design compounds and understand what a drug would aim at.
The platform can also work with ProtNLM, a deep learning model Google built. ProtNLM looks through UniProt, a large public database of proteins, and picks out ones that are poorly described. Those can be marked as possible new targets for antibacterial drugs.
Not a one-company race
Google is not alone here. MIT and other leading institutions are using generative AI to look for ways to fight high-risk infections, including drug-resistant gonorrhea and multidrug-resistant Staphylococcus aureus (MRSA).
The shared hope is that AI can speed up the discovery of new compounds, widen the range of chemistry and biology that can be explored, and make drug design more efficient and easier to explain.
What is still unknown
The report describes tools and intentions, not a new antibiotic or a clinical result. It gives no timeline, so treat it as an announcement of direction rather than a discovery.
What to watch
- Will DeepMind publish results or name partners for its AMR work?
- Will any protein targets flagged by ProtNLM be tested in lab experiments?
Try it
When you see an AI-for-medicine headline, check for three things: named partners, a published method, and results other labs can verify.
Sources and links
- Reportingtechnews.tw: the article we sourced
Liked it? Say why
Add a line for other readers.
No account needed. We never show your email. Comments with links, ads or abuse are held and not shown. Your comment shows after a quick check.
Listen to the AI Wire headlines
Listen to the AI WireListen to our daily AI shows every morning: on your commute, in the shower, wherever you are
Listen to the daily showsFirst reported by technews.tw · Read the original. Written by the SI Agent News Desk from the reporting above.Written with AI from the source above. Every number is checked against the source. Spot a mistake? Corrections.